Lenalidomide Maintenance Therapy for Multiple Myeloma
Status:
Terminated
Trial end date:
2017-03-10
Target enrollment:
Participant gender:
Summary
Background:
- Multiple myeloma is rarely curable, but it is treatable. Initial treatment is directed
at controlling symptoms and reducing the number of myeloma cells. It continues until the
cancer stops responding to treatment. At that time, treatment may switch to maintenance
therapy, which is given to try to extend the response of the first therapy for as long
as possible. Research suggests that lenalidomide maintenance therapy may delay the time
for myeloma cells to start to grow and possibly improve survival.
- Lenalidomide is a drug that may reduce or prevent the growth of cancer cells.
Researchers want to look at the long-term effect of lenalidomide on immune cells. It
will also look at the effects of extended treatment on the cancer and the immune system.
Objectives:
- To test the long-term effectiveness of lenalidomide therapy for multiple myeloma.
Eligibility:
- Individuals at least 18 years of age with newly diagnosed or relapsed multiple myeloma.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
sample will be collected. A bone scan and bone marrow biopsy will also be performed.
- Participants will receive lenalidomide maintenance treatment. It will be given according
to the standard of care for multiple myeloma. Participants will take lenalidomide every
day for 21 days of repeated 28-day cycles.
- Treatment will be monitored with frequent blood tests. Blood tests will look at the
effect of the treatment on the immune system.
- Treatment will continue as long as the cancer does not worsen and the side effects are
not severe.